BAT7104 / Bio-Thera Solutions - LARVOL DELTA

BAT7104 Injection in Patients With Advanced Malignant Tumors. (clinicaltrials.gov) - P1 | N=86 | Completed | Sponsor: Bio-Thera Solutions | Recruiting ➔ Completed | N=42 ➔ 86

Enrollment change • Trial completion • Hematological Malignancies • Hepatocellular Cancer • Solid Tumor

BAT7104 Injection in Patients with Advanced Malignant Tumors. (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Bio-Thera Solutions | Phase classification: P1a/1b ➔ P1 | Trial completion date: Jan 2024 ➔ Dec 2024 | Trial primary completion date: Jan 2024 ➔ Dec 2024

Metastases • Phase classification • Trial completion date • Trial primary completion date • Hematological Malignancies • Hepatocellular Cancer • Oncology • Solid Tumor

BAT7104 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=14 | Completed | Sponsor: Bio-Thera Solutions | Active, not recruiting ➔ Completed | N=29 ➔ 14 | Trial completion date: Dec 2024 ➔ Jun 2024 | Trial primary completion date: Sep 2024 ➔ Jun 2024

Enrollment change • Metastases • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Bio-Thera’s BAT8008 (ADC-Trop2) combined with bevacizumab or BAT7104 (PD-L1/CD47) for the treatment of advanced solid tumors has been approved for clinical trials [Google translation] (Bio-thera Press Release) - "The company announced today that it has recently received the 'Notice of Approval for Drug Clinical Trial' approved and issued by the National Medical Products Administration, and the company's application for clinical trials of its investigational drug BAT8008 in combination with bevacizumab or BAT7104 for the treatment of advanced solid tumors has been approved."

New trial • Oncology • Solid Tumor

BAT7104 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=29 | Active, not recruiting | Sponsor: Bio-Thera Solutions | Trial primary completion date: Jan 2024 ➔ Sep 2024

Metastases • Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor

Biotech: BAT7104 injection combined with BAT4706 injection for the treatment of advanced malignant tumors received drug clinical trial approval notice [Google translation] (STCN) - "...Biotech (688177) announced on the evening of January 11 that the company recently received a drug clinical trial approval notice approved and issued by the State Food and Drug Administration. The company’s drug under development, BAT7104 injection, is combined with BAT4706 injection. Clinical trial application for advanced malignancy approved."

New trial • Oncology

BAT7104 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=29 | Active, not recruiting | Sponsor: Bio-Thera Solutions | Recruiting ➔ Active, not recruiting | Trial primary completion date: Apr 2023 ➔ Jan 2024

Enrollment closed • Metastases • Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor

BAT7104 Injection in Patients With Advanced Malignant Tumors. (clinicaltrials.gov) - P1a/1b | N=42 | Recruiting | Sponsor: Bio-Thera Solutions

Metastases • New P1 trial • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Oncology • Solid Tumor

BAT7104 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=29 | Recruiting | Sponsor: Bio-Thera Solutions | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor

Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT7104, a Bispecific Antibody Targeting PD-L1 and CD47 for the Treatment of Advanced Solid Tumors (Businesswire) - "Bio-Thera Solutions...announced that dosing has begun in a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of BAT7104, a bispecific antibody that specifically blocks the interaction of human PD-L1 and CD47 with their corresponding receptors....The Phase 1, multi-center, open-label, dose-escalation clinical trial of BAT7104 is designed to assess the safety and tolerability of BAT7104. Key objectives of the study are to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D), and to evaluate pharmacokinetics and preliminary efficacy in patients with advanced solid tumor."

Trial status • Oncology • Solid Tumor

BAT7104 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1; N=29; Not yet recruiting; Sponsor: Bio-Thera Solutions

Clinical • New P1 trial • Hepatocellular Cancer • Oncology • Solid Tumor